ArticleScientific reports2017
Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review.Frontiers in medicine · 2025Pooled it
- New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing.International journal of environmental research and public health · 2023Pooled it
- Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review.Medicina oral, patologia oral y cirugia bucal · 2020Pooled it
- Soluble immune checkpoints are elevated in patients with primary biliary cholangitis.European journal of medical research · 2023Article
- Role of autoantibodies in the clinical management of primary biliary cholangitis.World journal of gastroenterology · 2023Review
- Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.PloS one · 2023Article
- Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance.Frontiers in immunology · 2018Review
- Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease.PloS one · 2018Article
- Biomarkers for primary biliary cholangitis: current perspectives.Hepatic medicine : evidence and research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum anti-mitochondrial antibody type 2 (AMA-M2) is considered as a pivotal biomarker for the diagnosis of primary biliary cholangitis (PBC). However, serological tests have many limitations, including inconvenience, invasiveness, and infection risks. Thus, a less invasive approach to detect AMA-M2 titer is desirable. We examined salivary AMA-M2 of potential PBC patients and found that AMA-M2 could be detected only in saliva of serum AMA-M2-positive PBC patients, but not in saliva of serum AMA-M2-negative PBC patients, oral lichen planus patients (OLP) patients, or healthy controls. Furthermore, the concentration of salivary AMA-M2 was positively correlated with the amount of serum AMA-M2 in patients. The salivary inflammatory cytokines were increased in the PBC, consistent with the results of serum test. These findings indicated that saliva might be a less invasive and cost-effective medium to accurately test for AMA-M2 levels and this is a promising development for the diagnosis and monitoring of PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.